Sun Yat-sen University: Lymphoma, T-Cell, Peripheral trials

The registry lists 24 Lymphoma, T-Cell, Peripheral studies with Sun Yat-sen University as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 1 7Phase 2 18Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell LymphomaNot yet recruitingNCT07615283Phase 1/2
• Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT07093710Phase 1/2
• Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Not yet recruitingNCT07032532Phase 2
• A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCLRecruitingNCT06855823Phase 1/2
• Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06793956Phase 1
• Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
• Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTLRecruitingNCT06406556Phase 2
• Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingNCT05572983Phase 2
• Prognostic Nomogram of Extranodal NK/T-cell LymphomaRecruitingNCT04554511
• A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)RecruitingNCT04365036Phase 3
• Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
• Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell LymphomaActive, not recruitingNCT05949944Phase 1/2
• A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell LymphomaStatus unknownNCT05527275Phase 1/2
• Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell LymphomaActive, not recruitingNCT05464433Phase 1/2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
• Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLStatus unknownNCT04676789Phase 2
• Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell LymphomaStatus unknownNCT04423536
• Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2
• Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknownNCT03321890Phase 2
• Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early StageTerminatedNCT02359162Phase 3
• Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX ChemotherapyStatus unknownNCT02229682Phase 2
• GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell LymphomaStatus unknownNCT01991158Phase 2
• Avastin+ GemAOD As First-Line Treatment in NK/T Cell LymphomaStatus unknownNCT01921790Phase 2
• A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma PatientsStatus unknownNCT01788137Phase 3